Literature DB >> 2719898

Variable metabolism of pinacidil: lack of correlation with the debrisoquine and trimethylamine C- and N-oxidative polymorphisms.

R Ayesh1, M Al-Waiz, A McBurney, S C Mitchell, J R Idle, J W Ward, R L Smith.   

Abstract

1. The urinary excretion of pinacidil and its N-oxide in man was found to vary over a five-fold range. 2. Studies in individuals with inherited deficiencies for C-hydroxylation (debrisoquine type) and trimethylamine N-oxidation showed that the N-oxidation of pinacidil did not co-segregate with these oxidative polymorphisms. 3. It is concluded that the variable N-oxidation of pinacidil is most likely to be due to variations in the activity of the P-450 isozymes rather than in the microsomal flavoprotein containing mixed-function amine oxidase of Ziegler which is considered to be responsible for the N-oxidation of trimethylamine.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2719898      PMCID: PMC1379720          DOI: 10.1111/j.1365-2125.1989.tb05389.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  13 in total

Review 1.  Differentiation of various types of biological oxidation of nitrogen in organic compounds.

Authors:  J W Gorrod
Journal:  Chem Biol Interact       Date:  1973-11       Impact factor: 5.192

2.  Microsomal oxidase. IV. Properties of a mixed-function amine oxidase isolated from pig liver microsomes.

Authors:  D M Ziegler; C H Mitchell
Journal:  Arch Biochem Biophys       Date:  1972-05       Impact factor: 4.013

3.  Serum concentrations and urinary excretion of pinacidil and its major metabolite, pinacidil pyridine-N-oxide following i.v. and oral administration in healthy volunteers.

Authors:  A McBurney; P R Farrow; S Ainsworth; J W Ward
Journal:  Br J Clin Pharmacol       Date:  1985-01       Impact factor: 4.335

4.  Trimethylaminuria ('fish-odour syndrome'): a study of an affected family.

Authors:  M Al-Waiz; R Ayesh; S C Mitchell; J R Idle; R L Smith
Journal:  Clin Sci (Lond)       Date:  1988-03       Impact factor: 6.124

5.  Hemodynamic characterization of pinacidil in rats. Comparison with hydralazine.

Authors:  M J Thoolen; J C Van Meel; B Wilffert; P B Timmermans; P A van Zwieten
Journal:  Pharmacology       Date:  1983       Impact factor: 2.547

6.  Studies on the mechanism of hepatic microsomal N-oxide formation. The role of cytochrome P-450 and mixed-function amine oxidase in the N-oxidation of NN-dimethylaniline.

Authors:  P Hlavica; M Kehl
Journal:  Biochem J       Date:  1977-06-15       Impact factor: 3.857

7.  A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population.

Authors:  D A Evans; A Mahgoub; T P Sloan; J R Idle; R L Smith
Journal:  J Med Genet       Date:  1980-04       Impact factor: 6.318

8.  Pharmacokinetics and hypotensive effect in healthy volunteers of pinacidil, a new potent vasodilator.

Authors:  J W Ward; A McBurney; P R Farrow; P Sharp
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

9.  Pharmacokinetics and distribution of the new antihypertensive agent pinacidil in rat, dog and man.

Authors:  E Eilertsen; J W Hart; M P Magnussen; H Sørensen; E Arrigoni-Martelli
Journal:  Xenobiotica       Date:  1982-03       Impact factor: 1.908

10.  Polymorphic hydroxylation of Debrisoquine in man.

Authors:  A Mahgoub; J R Idle; L G Dring; R Lancaster; R L Smith
Journal:  Lancet       Date:  1977-09-17       Impact factor: 79.321

View more
  2 in total

Review 1.  Pinacidil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the treatment of hypertension.

Authors:  H A Friedel; R N Brogden
Journal:  Drugs       Date:  1990-06       Impact factor: 9.546

2.  Metabolism of verapamil in a family pedigree with deficient N-oxidation of trimethylamine.

Authors:  R Ayesh; H Kroemer; M Eichelbaum; R L Smith
Journal:  Br J Clin Pharmacol       Date:  1991-06       Impact factor: 4.335

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.